What is Sofwave? The technology, stated plainly

Sofwave is a non-invasive ultrasound device built on SUPERB (Synchronous Ultrasound Parallel Beam) technology and manufactured by Sofwave Medical Ltd. Seven transducers sit in direct contact with the skin and fire simultaneously with each pulse, delivering high-frequency, non-focused ultrasound at 10–12 MHz to a fixed focal depth of about 1.5 mm, the mid-dermis. Peer-reviewed reports describe thermal zones spanning roughly 0.5 to 2 mm and reaching about 60–70 °C, an integrated contact cooling system with a real-time skin-temperature monitor to protect the epidermis, and sessions of roughly 30 to 60 minutes. It is FDA-cleared for facial lines and wrinkles, for lifting the eyebrow and lax submental and neck tissue in adults aged 22 and over, for short-term improvement in the appearance of cellulite, for acne scars, and for upper-arm skin laxity.

What the device does to tissue

Ultrasound in aesthetic dermatology works by absorption: tissue converts acoustic energy into heat. Raise a small volume of dermis into the roughly 60–70 °C range and collagen denatures in a controlled way, which starts a wound-healing response: fibroblast activation, then new collagen and elastin over the following months. Every device in this category is a different answer to the same engineering question: how do you put that heat where you want it without injuring the skin surface on the way in?

Sofwave's answer is geometric. Rather than focusing energy to a point, the seven transducers emit parallel, non-focused beams that heat a continuous band at one depth. The epidermis is not avoided by aiming around it; it is actively cooled from the contact surface while the beams pass through, with a temperature monitor watching the surface in real time. The consequence is that Sofwave has a single treatment plane rather than a set of selectable ones, which is the central fact to understand about it.

Where 1.5 mm sits, anatomically

A fixed 1.5 mm focal depth places the energy in the mid-dermis: below the epidermis and papillary dermis, within the reticular dermis where the bulk of structural collagen sits, and above the subcutaneous fat and the SMAS. A 2024 histopathology study of facial skin treated with the parallel-beam device confirmed the thermal effect was restricted to the dermal layer, with collagen remodelling documented at 1–3 mm from the epidermis and measurable increases in collagen and elastic fibre density at two months. A 2025 study using serial human biopsies out to ten months described continuing collagen, elastin and glycosaminoglycan changes across the whole follow-up period. That author group includes employees of the manufacturer, which is disclosed in the reference list below and is worth weighing.

This is also why Sofwave is not marketed as a fat-reducing or deep-plane device. The energy does not reach the subcutaneous compartment, and a device that does not reach a tissue plane cannot remodel it.

Device parameters as reported in the literature

What the FDA has and has not cleared

Clearance language matters, because "FDA cleared" is often stretched in advertising to mean more than it does. The Sofwave system received its first US clearance in 2019 for improvement of facial lines and wrinkles. In November 2021 the FDA cleared additional indications for lifting the eyebrow and lifting lax submental and neck tissue in subjects aged 22 and older. Short-term improvement in the appearance of cellulite followed in December 2022, treatment of acne scars in August 2023, and improvement of the appearance of upper-arm skin laxity in December 2023.

Everything outside that list is off-label use, whatever a marketing page says. Clearance is also not a promise of individual outcome: it means the manufacturer demonstrated substantial equivalence and reasonable safety for that indication, not that any given patient will respond.

What the published evidence supports

The clinical literature on this device is real but modest in size, and it is honest to say so. A 2023 study of 36 participants measured nasolabial fold and marionette line depression volume with 3D imaging and found statistically significant reduction at one and three months, with no significant further change between those two visits and no adverse events reported. A 2023 prospective trial of 15 subjects aged 40–69 assessed eyebrow, submental and neck lifting after two sessions and found improvement in all treated areas that was stable at three and six months. A 2024 study of 34 patients using a directional treatment technique measured an average tissue contraction of about 1.9 mm at eight weeks, essentially unchanged at 24 weeks. A 2025 retrospective series of 14 Asian patients treated for acne scars in a single session reported significant reduction in scar depression volume with follow-up out to eight months.

These are small, mostly single-arm studies with short follow-up, several of them in Asian skin types, and pain scores in them range from about 3.9 to 6.6 on a 0–10 scale, which is meaningfully uncomfortable for some people. What the evidence supports is a gradual, measurable change in the treated plane with a favourable safety record in the reported series. What it does not support is a fixed duration, a guaranteed magnitude, or a claim of permanence.

For the microfocused-ultrasound side of this comparison in equivalent depth, see the Ultherapy specialty site operated by the same clinic.

How the treatment is delivered in practice

After the examination and cleansing, the treatment areas are mapped and the handpiece is passed over them in a planned pattern. The published protocols use pulse energies in the region of 3.0–4.2 J with two to three passes per area, and around 150–200 pulses to cover both cheeks; the specific plan is set at the clinic, not by a page. Most patients describe brief heat with each pulse. Topical anaesthetic is commonly used. Delight Dermatology's protocol for the treatment is described on the clinic's own Sofwave page.

Reasonable expectations about timing

Nothing about this treatment is immediate. Any tightening felt on the day is largely tissue oedema. The change the studies measure appears over weeks to months as new collagen is laid down, which is why the two-to-three-month visit is the meaningful assessment point and why re-treatment is a decision made by examination rather than by a calendar interval. The aftercare page sets out that timeline in detail.